A phase 2 double-blind, placebo controlled multi-center adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000; an inactivated recombinant Saccharomyces Cerevisiae expressing mutant Ras protein combined with a gemcitabine regimen versus a gemcitabine regimen with placebo, in patients with post-resection R0/R1 pancreatic cancer with tumor sequence confirmation of Ras mutations
Latest Information Update: 08 Apr 2015
At a glance
- Drugs GI 4000 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlobeImmune
- 05 Apr 2015 Planned End Date changed from 1 May 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.